Sanofi's Amlitelimab Shows Clinically Meaningful Efficacy In Phase 2 Asthma Study, Phase 3 Program In Planning

Benzinga · 04/15 06:19

Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD

  • New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma
  • Lunsekimig now targeting chronic rhinosinusitis and COPD in addition to asthma
  • Itepekimab expanding into chronic rhinosinusitis along with COPD and bronchiectasis; phase 3 readouts in COPD in H2 2025 and bronchiectasis in 2026